Clinical efficacy and safety of fanhdi<sup>®</sup>, a plasma-derived VWF/Factor VIII concentrate, in von willebrand disease in Spain: a retrospective study
AuthorJiménez Yuste, Víctor Manuel; Álvarez Roman, María Teresa; Palomo Bravo, Ángeles; Galmes, Bernardo J.; Nieto Hernández, Maria del Mar; Benítez Hidalgo, Olga; Marzo Alonso, Cristina; Pérez González, Noelia Florencia; Coll, Julia; Núñez, Ramiro; Carrasco, Marina; García Candel, Faustino; Gonzalez-Porras, Jose Ramon; Hernández García, Carmen; Varó Castro, Maria José; Mir, Roser
EntityUAM. Departamento de Medicina
10.1177/10760296221074348Clinical and Applied Thrombosis/Hemostasis 28 (2022): 1-11
ISSN1076-0296 (print); 1938-2723 (online)
Funded byThe author(s) disclosed receipt of the followingfinancial support forthe research, authorship, and/or publication of this article: This workwas supported by Grifols, manufacturer of the pdVWF/FVIII,Fanhdi®
Subjectsbleeding; plasma-derived von willebrand factor/factor VIII concentrate; prophylaxis; surgery; von willebrand disease; von willebrand factor; Medicina
Rights© The Author(s) 2022
Esta obra está bajo una licencia de Creative Commons Reconocimiento-NoComercial 4.0 Internacional.
To evaluate the efficacy and safety of a plasma-derived factor VIII concentrate containing von Willebrand Factor (pdVWF/FVIII) in standard clinical practice in von Willebrand Disease (VWD) patients. Methods: A retrospective, multicentric, observational study of VWD patients treated with Fanhdi®, a pdVWF/FVIII concentrate, from January 2011 to December 2017 was conducted at 14 centers in Spain. Efficacy and safety were evaluated for acute bleeding episodes, for prevention of bleeding in surgeries, and for secondary long-term prophylaxis. Seventy-two eligible patients, type 1, 2, 3 VWD (25%/38.9%/36.1%) were treated for spontaneous and traumatic bleeding (140 episodes, n = 41 patients), to prevent surgical bleeding (69 episodes, n = 43 patients); and for secondary long-term prophylaxis (18 programs, n = 13 patients). Replacement therapy with pdVWF/FVIII showed an excellent to good clinical efficacy in 96.7% of the bleeding episodes, 100% during surgical procedures and 100% during prophylaxis. No adverse events (AEs), nor serious AEs related to the product were observed. Conclusions: Fanhdi® was effective, safe and well tolerated in the management of bleeding episodes, the prevention of bleeding during surgeries, and for secondary long-term prophylaxis in VWD patients
Google Scholar:Jiménez Yuste, Víctor Manuel - Álvarez Roman, María Teresa - Palomo Bravo, Ángeles - Galmes, Bernardo J. - Nieto Hernández, Maria del Mar - Benítez Hidalgo, Olga - Marzo Alonso, Cristina - Pérez González, Noelia Florencia - Coll, Julia - Núñez, Ramiro - Carrasco, Marina - García Candel, Faustino - Gonzalez-Porras, Jose Ramon - Hernández García, Carmen - Varó Castro, Maria José - Mir, Roser
This item appears in the following Collection(s)
Showing items related by title, author, creator and subject.
Safety and efficacy clinical trials for SYL1001, a novel short interfering RNA for the treatment of dry eye disease Benitez-Del-Castillo, José Manuel; Moreno-Montañés, Javier; Jiménez-Alfaro, Ignacio; Muñoz-Negrete, Francisco José; Turman, Krista; Palumaa, Kadi; Sádaba, Belén; González, María Victoria; Ruz, Verónica; Vargas, Beatriz; Pañeda, Covadonga; Martínez, Tamara; Bleau, Anne Marie; Jimenez, Ana Isabel
First-in-human phase I clinical trial of a TLR4-binding DNA aptamer, ApTOLL: Safety and pharmacokinetics in healthy volunteers Hernández-Jiménez, Macarena; Martín-Vílchez, Samuel; Ochoa Mazarro, María Dolores; Mejía-Abril, Gina; Román, Manuel; Camargo-Mamani, Paola; Luquero-Bueno, Sergio; Jilma, Bernd; Moro, María A.; Fernández, Gerónimo; Piñeiro, David; Ribó, Marc; González, Víctor M.; Lizasoain, Ignacio; Abad Santos, Francisco